These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33076728)

  • 21. PD-L1 Mediates Dysfunction in Activated PD-1
    Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
    Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
    Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
    Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
    Qin X; Liu C; Zhou Y; Wang G
    Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1366-72. PubMed ID: 20937224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatoma cells up-regulate expression of programmed cell death-1 on T cells.
    Chen J; Wu XJ; Wang GQ
    World J Gastroenterol; 2008 Nov; 14(44):6853-7. PubMed ID: 19058313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
    Durgan K; Ali M; Warner P; Latchman YE
    Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
    He G; Zhang H; Zhou J; Wang B; Chen Y; Kong Y; Xie X; Wang X; Fei R; Wei L; Chen H; Zeng H
    J Exp Clin Cancer Res; 2015 Nov; 34():141. PubMed ID: 26581194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel signature based on pairwise PD-1/PD-L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma.
    Zhao E; Chen S; Dang Y
    Clin Transl Med; 2021 May; 11(5):e431. PubMed ID: 34047473
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.
    Lee SWL; Adriani G; Ceccarello E; Pavesi A; Tan AT; Bertoletti A; Kamm RD; Wong SC
    Front Immunol; 2018; 9():416. PubMed ID: 29559973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The suppressive effect of co-inhibiting
    Liang L; Ge K; Zhang F; Ge Y
    Cell Mol Biol Lett; 2018; 23():58. PubMed ID: 30564277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
    Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
    Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
    Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
    [